



For a **healthier** planet

:CZ VACCINES



THE COMPANY :

In CZ Vaccines biotechnology is our goal.
And the prevention of animal diseases is
our mission.

**+ 65 countries : + 200 staff : + 100 strains :
45.000 m² manufacturing facilities**

CZ Vaccines was created in 1993 within a pharmaceutical framework boasting more than 80 years' experience; today CZ Vaccines, is a renowned company focusing on animal health.

Over the years we have become a world leader in biotechnology, developing, manufacturing, and marketing vaccines and medicines for animal health in many countries worldwide.

World leader in mycobacteria
Main European supplier of bluetongue
and clostridial vaccines

LEADING PRODUCTS

LEADER VACCINES FOR RUMINANTS

SILIRUM AND GUDAIR

Paratuberculosis inactivated vaccines for cattle and sheep

BLUEVAC

Inactivated vaccines against bluetongue virus for ruminants. Serotypes 1, 4, 8

DILPHES AND ALGONTEX

Pasteurella and agalaxia inactivated vaccines for ruminants

CUBOLAC

Clostridial inactivated vaccine for ruminants

LEADER VACCINES FOR SWINE

IBERITEX

Erysipela swine inactivated

E. COLI VACCINE

Multi-strain swine vaccine

PHARMACOLOGICAL INJECTABLE

HIPPIRON

Iron solution for racing horses

BIOLOGICALS FOR GOVERNMENT TENDERS

AVIAN AND BOVINE PPD TUBERCULINS

Bovine and avian diagnostic test for ruminants

BLUEVAC

Inactivated vaccines against bluetongue virus for ruminants. Serotypes 1, 4, 8

ETADEX

Rabies inactivated. For dog, cats and bovine

OCUREV

Brucella melitensis. Active immunization in sheep and goats. Ocular route

B-19 CZV

Brucella abortus. Active immunization in cattle

CZV REV-1

Brucella melitensis. Active immunization in sheep and goats

RB-51 CZV

Brucella abortus. Active immunization in cattle

B-19 CZV OPHTHALMIC

Brucella abortus. Active immunization in cattle. Ocular route

ROSE BENGAL TEST

Serological diagnosis of infections by brucella for ruminants

CMO

The world's largest multinational
veterinary pharma companies outsource
with CZ Vaccines

CZ Vaccines provides its clients with a comprehensive service. Our products are manufactured according to the individual needs and specifications of each client, and we offer our products at different stages of production: cultures, semi-finished products, and ready for sale final products.



R&D :


Biotechnology research and development are the hallmark of the CZ Vaccines business model. The company allocates 11% of its annual revenue to strengthen its R&D efforts.

Our R&D team has extensive scientific experience and up-to-date technologies in biotechnology and vaccines and we have a modern and sophisticated equipments in our R&D laboratories.

We allocate 11% annually to
R + D + i

MANUFACTURING :

- ÿ Clostridia
- ÿ Aerobic bacteria
- ÿ Brucella
- ÿ Mycoplasma
- ÿ Mycobacteria
- ÿ Bovine and avian tuberculin diagnosis test
- ÿ Virus in monolayer and suspension cell cultures
- ÿ Lyophilised (freeze-dried) products
- ÿ Cellular therapy
- ÿ Oil emulsions
- ÿ Injectables
- ÿ Vaccine adjuvants



Production plants

Suspension cell/virus cultures plant

Fermentation and inactivation vessels. Fermenters. Centrifuge, microfiltration and ultrafiltration.

Brucella vaccines plant

Fermentation and inactivation vessels. Production of live antigen for lyophilisation.

Mycobacteria plant: *Mycobacterium avium/bovis/paratuberculosis*

Culture and processing.

Aerobic culture plant

Fermentation and inactivation vessels: up to 2,000 litres. Centrifuge, microfiltration and ultrafiltration.

Clostridial vaccines plant

Fermentation and inactivation vessels: up to 5,000 litres. Centrifuge, microfiltration and ultrafiltration.

Blending area

Vessels: from 100 litres to 5,000 litres.

Media production suite

Vessels of up to 4,000 litres. 4 independent filtration lines.

Lyophilisation (freeze-drying)

4 Lyophilisers: capacity of 80-100 kilograms, vial load capacity of up to 17,000 vials.

Antigen storage

3x3,000 litres and 6x2,000 litres.

Sterile filling

2 plants with 4 filling lines: vials from 0.2 mL to 1000 mL.

Pharma production plant

Iron sucrose 700 L per week.

	R&D	CO-DEVELOPMENT	TECH TRANSFER	MANUFACTURING	REGULATORY	MARKETING	DISTRIBUTION
START UPS/SPIN-OFF	●	●	●	●	●	●	●
LABORATORIES AND MULTINATIONALS	●	●	●	●	●	●	●
GOVERNMENTS	●			●		●	
DISTRIBUTORS		●	●	●	●	●	



REGULATORY :

The Regulatory Affairs Department has extensive experience in the field of international pharmaceutical law, from dossier submission to obtaining marketing authorizations.


MARKETING :

Our own products are distributed by third companies, to which we provide commercial and marketing support, in 65 countries worldwide.

Our plant of mycobacteria is the largest in the world, with capacity for 150 million doses of tuberculin

Over 20 different types of aerobic bacteria are used at the aerobic culture plant

ONE HEALTH : ONE PLANET



Ongoing Global Challenges : emerging infectious diseases : increased demand for animal-based protein for an increasingly crowded world : antibiotic resistance : climate change

Animal health care is indispensable for a healthy planet. Vaccines and biotechnology are the key tool for disease prevention and open the door to a healthier and more sustainable planet.

We firmly believe that vaccines and biotechnology is a key tool for disease prevention. In CZ Vaccines we work daily with our partners to build a healthier planet, a better planet.

www.czvaccines.com

A COMPANY OF ZENDAL GROUP

For a **healthier** planet

:CZ VACCINES